The short answer
GLP-1s are not FDA-approved for prediabetes, but are prescribed off-label or through a weight-management indication, and trials show they cut progression to type 2 diabetes.
Zepbound specifically
Off-label for prediabetes; on-label for obesity. SURMOUNT data showed strong glycemic improvement.
BMI & eligibility
For prediabetes, coverage almost always runs through the weight-management door: BMI ≥30, or ≥27 with a comorbidity such as hypertension or dyslipidemia.
Check your BMI
BMI calculator
BMI 27-29.9 — eligible if comorbidity (T2D, hypertension, sleep apnea, PCOS).
BMI is one signal among several. Waist circumference, body composition, metabolic markers, and clinical history also matter — talk to a prescriber.
Insurance & coverage
Prediabetes is not a covered indication on its own. Qualify through obesity (Wegovy/Zepbound) or wait until A1c ≥6.5% for a diabetes pathway (Ozempic/Mounjaro). Cash-pay or compounded routes are common for prediabetes patients who don’t meet BMI thresholds.
Check if your plan covers itWe earn affiliate commissions from listed providers. See our editorial standards.
Other GLP-1s for prediabetes
Zepbound for other conditions
Sources
Educational information, not medical advice. FDA-approval status reflects labeling as of 2026; off-label prescribing is legal and common but coverage varies.